NO921364L - Hybridpolypeptid - Google Patents

Hybridpolypeptid

Info

Publication number
NO921364L
NO921364L NO92921364A NO921364A NO921364L NO 921364 L NO921364 L NO 921364L NO 92921364 A NO92921364 A NO 92921364A NO 921364 A NO921364 A NO 921364A NO 921364 L NO921364 L NO 921364L
Authority
NO
Norway
Prior art keywords
polypeptide
hybrid
avidin
interest
high yield
Prior art date
Application number
NO92921364A
Other languages
English (en)
Other versions
NO921364D0 (no
Inventor
Dean Ervin Cress
Ferdinand Carl Haase
Original Assignee
Rohm & Haas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rohm & Haas filed Critical Rohm & Haas
Publication of NO921364D0 publication Critical patent/NO921364D0/no
Publication of NO921364L publication Critical patent/NO921364L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/675—Beta-endorphins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1018—Carboxy- and carbamoyl transferases (2.1.3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Det omtales et hybridpolypeptid som omfatter et avidin- bindingspolypeptid som inneholder et biotinbindingsområde fusjonert med et interesserede polypeptid hvor avidinbindings- "polypeptidet befinner seg "oppstrøms" for det interesserende polypeptid. Hybridpolypeptidet fremstilles ved rekombinant DNA-teknikk. Hybridpolypeptidet kan også inneholde et spaltingssete for spalting av det interesserende polypeptid fra avidinbidingspolypeptidet ved anvendelse av egnet proteo- lytisk eller kjemisk middel. Hybridpolypeptidet uttrykkes i egnete vertceller transformert med DNA-ekspresjonsvektoren som koder for hybridpolypeptidet og kan utvinnes fra råcelle- ekstrakter i høyt utbytte og med høy renhet ved avidinaffini- tetskromatografi. Etter avidinaffinitetsrensingen kan interes- serende polypeptid fraspaltes og derved oppnås i en ren og høvaktiv tilstand.
NO92921364A 1991-04-19 1992-04-08 Hybridpolypeptid NO921364L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/687,819 US6072039A (en) 1991-04-19 1991-04-19 Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest

Publications (2)

Publication Number Publication Date
NO921364D0 NO921364D0 (no) 1992-04-08
NO921364L true NO921364L (no) 1992-10-20

Family

ID=24761988

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92921364A NO921364L (no) 1991-04-19 1992-04-08 Hybridpolypeptid

Country Status (13)

Country Link
US (1) US6072039A (no)
EP (1) EP0511747A1 (no)
JP (1) JPH06166698A (no)
KR (1) KR920019820A (no)
AU (1) AU659139B2 (no)
BR (1) BR9201437A (no)
CA (1) CA2064933A1 (no)
FI (1) FI921740L (no)
IE (1) IE921250A1 (no)
IL (1) IL101454A0 (no)
MX (1) MX9201749A (no)
NO (1) NO921364L (no)
NZ (1) NZ242395A (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
WO1996021156A1 (en) * 1995-01-04 1996-07-11 Abbott Laboratories Method for preparing scintillation proximity assay targets
EP1489100B1 (en) 1997-12-08 2016-06-15 Merck Patent GmbH Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
EP0985931A3 (en) * 1998-09-04 2000-03-29 Becton Dickinson and Company Recombinant antigen immunoassay for the diagnosis of syphilis
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
JP4793971B2 (ja) 1999-08-09 2011-10-12 メルク パテント ゲーエムベーハー 複合サイトカイン−抗体複合体
DE19952956A1 (de) 1999-11-03 2001-05-17 Acgt Progenomics Ag Verfahren zur Verbindung von molekularen Substanzen
EP1228214A2 (en) 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
DE60129695T2 (de) 2000-06-29 2008-06-05 Merck Patent Gmbh Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
US20020142355A1 (en) * 2000-11-14 2002-10-03 Baylor College Of Medicine Methods for the in vivo biotin labeling of polypeptides
AU2002248571B2 (en) 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
PT1383785E (pt) 2001-05-03 2011-06-28 Merck Patent Gmbh Anticorpo recombinante específico de tumores e utilização deste
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
PT1454138E (pt) 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
CA2467736A1 (en) * 2001-12-05 2003-06-19 Large Scale Biology Corporation Flexible method and apparatus for high throughput production and purification of multiple proteins
GB0202018D0 (en) * 2002-01-29 2002-03-13 Sense Proteomic Ltd Tag and method
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
CN100432105C (zh) 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
EP1636270B1 (en) 2003-06-16 2016-07-20 UCB Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
CA2551915C (en) 2003-12-30 2015-06-23 Merck Patent Gesellschaft Mit Beschraenkter Haftung Il-7 fusion proteins
JP2008504008A (ja) 2003-12-31 2008-02-14 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質
PL1706428T3 (pl) 2004-01-22 2010-02-26 Merck Patent Gmbh Przeciwciała przeciwnowotworowe o zredukowanym wiązaniu dopełniacza
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
CN101072793B (zh) 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
DE102005040347A1 (de) 2005-08-25 2007-03-01 Profos Ag Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von Listerien
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
BRPI0620648B1 (pt) 2005-12-30 2022-12-20 Merck Patent Gesellschaft Mit Beschrãnkter Haftung Variante de il-12 p40, proteínas il-12, il-23 e de fusão, composição farmacêutica e uso da mesma
PL2005185T3 (pl) 2006-03-22 2011-05-31 Viral Logic Systems Tech Corp Sposoby identyfikowania celów polipeptydowych
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2421896A1 (en) 2009-04-22 2012-02-29 Merck Patent GmbH Antibody fusion proteins with modified fcrn binding sites
EP2527431A1 (en) 2011-05-26 2012-11-28 bioMérieux S.A. Novel Listeria bacteriophage tailspike protein and uses thereof
US20150099860A1 (en) * 2013-10-08 2015-04-09 Proteins Easy Corp Methods for separating and purifying endogenous, exogenous and recombinant proteins/peptides from plants and animals using aqueous-free, anhydrous strategies
CN106156530A (zh) * 2016-08-03 2016-11-23 北京好运到信息科技有限公司 基于栈式自编码器的体检数据分析方法及装置

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839293A (en) * 1986-02-24 1989-06-13 The Trustees Of Columbia University In The City Of New York DNA encoding streptavidin, streptavidin produced therefrom, fused polypeptides which include amino acid sequences present in streptavidin and uses thereof
PT89121A (pt) * 1987-12-04 1989-12-29 Du Pont Processo para a preparacao de interleuquina-2 imobilizada e interleuquina-2 contendo uma extensao no terminal-carboxilo com actividade de interleuquina-2 natural
WO1989009393A1 (en) * 1988-03-24 1989-10-05 Igen, Inc. Luminescent chimeric proteins
CA2057908A1 (en) * 1989-05-19 1990-11-20 John E. Cronan, Jr. Fusion proteins having an in vivo post-translational modification site and methods of manufacture and purification
DE69434520T3 (de) * 1993-07-30 2009-10-15 Affymax, Inc., Palo Alto Biotinylierung von proteinen

Also Published As

Publication number Publication date
BR9201437A (pt) 1992-12-01
US6072039A (en) 2000-06-06
FI921740A7 (fi) 1992-10-20
KR920019820A (ko) 1992-11-20
IE921250A1 (en) 1992-10-21
MX9201749A (es) 1992-10-01
CA2064933A1 (en) 1992-10-20
EP0511747A1 (en) 1992-11-04
AU1398792A (en) 1992-10-22
FI921740A0 (fi) 1992-04-16
IL101454A0 (en) 1992-12-30
AU659139B2 (en) 1995-05-11
JPH06166698A (ja) 1994-06-14
NZ242395A (en) 1993-12-23
FI921740L (fi) 1992-10-20
NO921364D0 (no) 1992-04-08

Similar Documents

Publication Publication Date Title
NO921364L (no) Hybridpolypeptid
Sundkvist et al. Structure and function of free 40 S ribosome subunits: Characterization of initiation factors
AU3676595A (en) Expression and export technology of proteins as immunofusins
EP0824148A3 (en) Polyester synthase gene and process for producing polyester
AU2812484A (en) Dna vectors and there use in recombinant dna technology
DE69109109D1 (de) Ubiquitinspezifische protease.
ES2183960T3 (es) ,cj2, una cisteimproteasa apoptotica, y composiciones para producirla y metodos de utilizacion.
EP0236978A3 (en) Production of factor xiiia by gene technology
AU583388B2 (en) High performance liquid chromatography mobile phase
KR870004139A (ko) 인체 λ-인터페론의 생물학적 활성 유도체를 제조하는 방법
EA200000202A1 (ru) Рекомбинантная экспрессия c-пептида инсулина
Lai Studies on the structure of rabbit muscle aldolase: Determination of the primary structure of the COOH-terminal BrCN peptide; the complete sequence of the subunit polypeptide chain
ATE79409T1 (de) Herstellungsverfahren fuer humanes atriales natriuretisches polypeptid.
NZ334146A (en) Generating immortalised chicken cells to be used for propagating virus and producing recombinant proteins
ATE335079T1 (de) Rezeptor eines neurotrophen faktors (gfr-alpha-4)
HUT69979A (en) Method for producing protein c
IE810114L (en) N-benzyloxycarbonyl-l-aspartic acid
AU1093597A (en) Vector for expression of n-terminally extended proteins in yeast cell
KR860008283A (ko) 인체 췌장 엘라스타제의 제조방법
GB2073204A (en) Process for producing an insulin precursor
Qureshi et al. The isolation of acyl carrier protein from the pigeon liver fatty acid synthetase complex II
Polayes et al. Efficient protein expression and simple purification using the pPROEX-1 super (TM) system
Müller et al. The biosynthesis of a precursor of cartilage collagen by embryonic chicken sterna in the presence of α, α′-dipyridyl
DE59814240D1 (de) Hyaluronidase enthaltendes Präparat und pharmazeutische Verwendung davon
KR860008282A (ko) 재조합 사람 레닌의 제조방법